Eduardo Davila, Ph.D., received his Ph.D. degree from Mayo Clinic Graduate School of Biomedical Sciences in 2002, after initially coming to Mayo as a participant in the Postbaccalaureate Research Education Program (PREP). He received his B.S. from New Mexico State University.
As a student in the Mayo Immunology Ph.D. Program, he worked with Esteban Celis, M.D., Ph.D., to pioneer the use of TLR9 agonists and T cell-based tumor immunotherapy.
Dr. Davila is an associate professor of microbiology and immunology at the University of Maryland School of Medicine, as well as the program leader for the Tumor Immunology and Immunotherapy Research Program at the Greenebaum Cancer Center at the University of Maryland. His research interests focus on developing novel T cell-based cancer therapies.
Dr. Davila's research is currently supported by grants from the National Institutes of Health, Department of Veterans Affairs and private foundations.
Jan. 08, 2015